Single low-dose administration of pharmacological inhibitor of mitogen-activated ERK kinase to the adventitia of the injured rat carotid artery suppresses neointima formation and inhibits nuclear ERK signaling

European Journal of Pharmacology

Volumn 617, Issue 1-3, 2009, Pages 90-96

  Fahrenholz, Meike ^a   Real, Robert ^a   Küken, Anne ^a   Saxena, Amit ^a   Orzechowski, Hans Dieter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Arterial injury; MAP kinase; Neointima; Pluronic gel; Proliferation; Transcription factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POLOXAMER; TRANSCRIPTION FACTOR ETS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BIOCHEMISTRY; BLOOD VESSEL WALL; CAROTID ARTERY INJURY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CAROTID ARTERIES; CELL NUCLEUS; CELL PROLIFERATION; CONNECTIVE TISSUE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEIN C-ETS-1; RATS; RATS, SPRAGUE-DAWLEY; TUNICA INTIMA;

EID: 68549134923     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.040     Document Type: Article

References (46)

1. Ahn N.G., Nahreini T.S., Tolwinski N.S., and Resing K.A. Pharmacologic inhibitors of MKK1 and MKK2. Methods Enzymol. 332 (2001) 417-431
2. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., and Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270 (1995) 27489-27494
3. Anderson B.C., Pandit N.K., and Mallapragada S.K. Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels. J. Control. Release 70 (2001) 157-167
4. Bendeck M.P., Zempo N., Clowes A.W., Galardy R.E., and Reidy M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 75 (1994) 539-545
5. Bravo R. Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp. Cell Res. 163 (1986) 287-293
6. Canagarajah B.J., Khokhlatchev A., Cobb M.H., and Goldsmith E.J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90 (1997) 859-869
7. Chen D., Krasinski K., Sylvester A., Chen J., Nisen P.D., and Andres V. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99 (1997) 2334-2341
8. Cho A., and Reidy M.A. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res. 91 (2002) 845-851
9. Chuang C.F., and Ng S.Y. Functional divergence of the MAP kinase pathway. ERK1 and ERK2 activate specific transcription factors. FEBS Lett. 346 (1994) 229-234
10. Clowes A.W., Reidy M.A., and Clowes M.M. Mechanisms of stenosis after arterial injury. Lab. Invest. 49 (1983) 208-215
11. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
12. de Borst G.J., Ackerstaff R.G., de Vries J.P., vd Pavoordt E.D., Vos J.A., Overtoom T.T., and Moll F.L. Carotid angioplasty and stenting for postendarterectomy stenosis: long-term follow-up. J. Vasc. Surg. 45 (2007) 118-123
13. Douglas Jr. J.S. Pharmacologic approaches to restenosis prevention. Am. J. Cardiol. 100 (2007) 10K-16K
14. Eisenberg M.J., and Konnyu K.J. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am. J. Cardiol. 98 (2006) 375-382
15. Gennaro G., Menard C., Giasson E., Michaud S.E., Palasis M., Meloche S., and Rivard A. Role of p44/p42 MAP kinase in the age-dependent increase in vascular smooth muscle cell proliferation and neointimal formation. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 204-210
16. Gennaro G., Menard C., Michaud S.E., Deblois D., and Rivard A. Inhibition of vascular smooth muscle cell proliferation and neointimal formation in injured arteries by a novel, oral mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor. Circulation 110 (2004) 3367-3371
17. Goetze S., Kintscher U., Kaneshiro K., Meehan W.P., Collins A., Fleck E., Hsueh W.A., and Law R.E. TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis 159 (2001) 93-101
18. Graf K., Xi X.P., Yang D., Fleck E., Hsueh W.A., and Law R.E. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 29 (1997) 334-339
19. Gupta R., Al-Ali F., Thomas A.J., Horowitz M.B., Barrow T., Vora N.A., Uchino K., Hammer M.D., Wechsler L.R., and Jovin T.G. Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke. 37 (2006) 2562-2566
20. Heijenbrok F.J., van der Wal A.C., Pfaffendorf M., and van Zwieten P.A. Morphologic and functional consequences of intimal hyperplasia in the rat carotid artery. Naunyn-Schmiedeberg's Arch. Pharmacol. 357 (1998) 133-142
21. Hu Y., Cheng L., Hochleitner B.W., and Xu Q. Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2808-2816
22. Hultgardh-Nilsson A., Cercek B., Wang J.W., Naito S., Lovdahl C., Sharifi B., Forrester J.S., and Fagin J.A. Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. Circ. Res. 78 (1996) 589-595
23. Jeremias A., and Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann. Intern. Med. 148 (2008) 234-238
24. Jinnin M., Ihn H., Mimura Y., Asano Y., Yamane K., and Tamaki K. Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Res. 33 (2005) 3540-3549
25. Johnson G.L., and Vaillancourt R.R. Sequential protein kinase reactions controlling cell growth and differentiation. Curr. Opin. Cell Biol. 6 (1994) 230-238
26. Kerzee J.K., and Ramos K.S. Activation of c-Ha-ras by benzo(a)pyrene in vascular smooth muscle cells involves redox stress and aryl hydrocarbon receptor. Mol. Pharmacol. 58 (2000) 152-158
27. Khalil R.A., and Morgan K.G. PKC-mediated redistribution of mitogen-activated protein kinase during smooth muscle cell activation. Am. J. Physiol. 265 (1993) C406-C411
28. Koyama H., Olson N.E., Dastvan F.F., and Reidy M.A. Cell replication in the arterial wall: activation of signaling pathway following in vivo injury. Circ. Res. 82 (1998) 713-721
29. Lille S., Daum G., Clowes M.M., and Clowes A.W. The regulation of p42/p44 mitogen-activated protein kinases in the injured rat carotid artery. J. Surg. Res. 70 (1997) 178-186
30. Liu B., Fisher M., and Groves P. Down-regulation of the ERK1 and ERK2 mitogen-activated protein kinases using antisense oligonucleotides inhibits intimal hyperplasia in a porcine model of coronary balloon angioplasty. Cardiovasc. Res. 54 (2002) 640-648
31. Majerus M.A., Bibollet-Ruche F., Telliez J.B., Wasylyk B., and Bailleul B. Serum, AP-1 and Ets-1 stimulate the human ets-1 promoter. Nucleic Acids Res. 20 (1992) 2699-2703
32. Masoud I., Shapiro F., Kent R., and Moses A. A longitudinal study of the growth of the New Zealand white rabbit: cumulative and biweekly incremental growth rates for body length, body weight, femoral length, and tibial length. J. Orthop. Res. 4 (1986) 221-231
33. Nelson K.K., Subbaram S., Connor K.M., Dasgupta J., Ha X.F., Meng T.C., Tonks N.K., and Melendez J.A. Redox-dependent matrix metalloproteinase-1 expression is regulated by JNK through Ets and AP-1 promoter motifs. J. Biol. Chem. 281 (2006) 14100-14110
34. Orzechowski H.D., Gunther A., Menzel S., Zimmermann A., Funke-Kaiser H., Real R., Subkowski T., Zollmann F.S., and Paul M. Transcriptional mechanism of protein kinase C-induced isoform-specific expression of the gene for endothelin-converting enzyme-1 in human endothelial cells. Mol. Pharmacol. 60 (2001) 1332-1342
35. Palumbo R., Gaetano C., Melillo G., Toschi E., Remuzzi A., and Capogrossi M.C. Shear stress downregulation of platelet-derived growth factor receptor-beta and matrix metalloprotease-2 is associated with inhibition of smooth muscle cell invasion and migration. Circulation 102 (2000) 225-230
36. Reiners Jr. J.J., Lee J.Y., Clift R.E., Dudley D.T., and Myrand S.P. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol. Pharmacol. 53 (1998) 438-445
37. Ruef J., Hofmann M., and Haase J. Endovascular interventions in iliac and infrainguinal occlusive artery disease. J. Interv. Cardiol. 17 (2004) 427-435
38. Sharrocks A.D. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2 (2001) 827-837
39. Slupsky C.M., Gentile L.N., Donaldson L.W., Mackereth C.D., Seidel J.J., Graves B.J., and McIntosh L.P. Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphorylation site. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 12129-12134
40. Taki M., Verschueren K., Yokoyama K., Nagayama M., and Kamata N. Involvement of Ets-1 transcription factor in inducing matrix metalloproteinase-2 expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Int. J. Oncol. 28 (2006) 487-496
41. Trojanowska M. Ets factors and regulation of the extracellular matrix. Oncogene 19 (2000) 6464-6471
42. Weintraub W.S. The pathophysiology and burden of restenosis. Am. J. Cardiol. 100 (2007) 3K-9K
43. White L.A., Maute C., and Brinckerhoff C.E. ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) are auxiliary elements that regulate basal and phorbol-induced transcription. Connect. Tissue Res. 36 (1997) 321-335
44. Whitmarsh A.J., and Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74 (1996) 589-607
45. Yang B.S., Hauser C.A., Henkel G., Colman M.S., Van Beveren C., Stacey K.J., Hume D.A., Maki R.A., and Ostrowski M.C. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol. 16 (1996) 538-547
46. Zeller T. Current state of endovascular treatment of femoro-popliteal artery disease. Vasc. Med. 12 (2007) 223-234